RYAN DRANT – (Chairman of the Board)
Ryan Drant is the Founder and Managing Partner of Questa Capital, a healthcare-focused venture capital and growth equity investment firm. Ryan previously spent nineteen years at New Enterprise Associates (www.nea.com), where he served as a general partner, Head of Healthcare Investing and a member of the NEA Management Committee. Prior to NEA, he was in the corporate finance group at Alex. Brown & Sons and started his career at Arthur Andersen & Co.
Ryan is a four-time nominee to the Forbes Midas List of top venture capital investors. In addition to Intrinsic Therapeutics, he is currently a director of Bicycle Health, Calyxo, ControlRad, Cortica, Dispatch Health, Eko, Eximis, Medrio and Spine Wave. Ryan also serves on the board of the Medical Device Manufacturers Association and the National Venture Capital Association. He received a Bachelor of Arts degree in Political Science from Stanford University.
BRIAN VERRIER
Mr. Verrier is currently the President & CEO of Ossio, Inc. Ossio is an early stage company, founded out of Israel, focusing on transformational technology in the Orthopedic Fixation Market. Over the course of his 27 year career, Brian has held management and leadership positions at all levels. The majority of Brian’s career has been in the Cardiovascular and Peripheral Vascular markets. Most recently, Brian was the President of Covidien’s Peripheral Vascular Business Unit, which was eventually acquired in the January 2015 acquisition by Medtronic. Following Covidien’s 2010 acquisition of Minnesota based ev3, the Peripheral Vascular Business grew from $700m to $1.2b through six strategic acquisitions, as well as realized significant improvement in commercial execution, product development processes and portfolio management. Brian’s principles in leading businesses are centered around innovation and value creation for all stakeholders.
Brian holds an Economics Degree from the University of Connecticut and currently resides in Massachusetts with his wife Colleen and three children Sean, Ryan and Shea.
DAVE AMERSON
Dave Amerson served as President and CEO of NeoTract, Inc. until its acquisition by Teleflex in 2017 for $1.1 billion. Dave previously served as Chairman of the Board at Palette Life Sciences until its acquisition by Teleflex for $600 million in 2023 and was a Board Member of Relievant Medsystems, Inc. until its acquisition for by Boston Scientific in 2023. He currently serves on the board of directors of Calyxo, Moximed, Revelle and the Urology Care Foundation. He holds an M.B.A. from Argosy University and a B.A. in Political Science from the University of West Georgia.
TYLER BINNEY
Tyler Binney is currently President and CEO of Relievant Medsystems, which was recently acquired by Boston Scientific for $850 million plus a performance-based earnout. Prior to joining Relievant, Tyler served as President and General Manager of Interventional Urology at Teleflex, and as Vice President of Sales for NeoTract. Prior to NeoTract, Tyler served in multiple leadership roles in sales and marketing at Johnson & Johnson. Tyler holds a Bachelor of Science in Biology from Presbyterian College.
GREG LAMBRECHT
Prior to founding Intrinsic in 1999, Greg Lambrecht was a Vice President of Product Development & Marketing at Stryker, a global orthopedic implant company, where he directed the development and launch of numerous successful orthopedic implants. Greg also held various management positions in product and business development within Pfizer’s Medical Technology Group. The core of his career at Pfizer was implementing a process for inventing and developing new technologies that best met the needs of Pfizer’s physician customers worldwide.
Greg received a Bachelor of Science in Nuclear Engineering from the Massachusetts Institute of Technology in 1990 and returned to the same institution for a Masters Degree in Mechanical Engineering in 1993. Greg holds numerous patents in the fields of gynecology, general surgery, cardiology, and orthopedics.
KEITH VALENTINE
Keith Valentine has over thirty years of executive leadership and commercialization success at high-performing, growth-stage spine and orthopedics companies. He was most recently President and Chief Executive Officer of Orthofix, Inc. following its merger with SeaSpine, Inc. in 2023. Prior to the merger, Mr. Valentine served as President and Chief Executive Officer of SeaSpine, a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders, beginning in 2015.
Prior to joining SeaSpine, Keith served in various leadership capacities at NuVasive, Inc. from 2001-2015, including, most recently, President and Chief Operating Officer. From 1992 through 2000, he held leadership positions with Medtronic Spine & Biologics, most recently as that company’s Vice President of Marketing. He currently serves on various Boards including ATEC Spine, LocateBio as Non-Executive Chair, and at Regentis Biomaterials. Keith earned a B.B.A. from Western Michigan University and studies focused on Pre-Medicine from the University of Michigan